BrainTale Accelerates Its International Expansion and Unveils Tier-one Collaborations to Improve Brain Care and Enable Precision Neurology
May 06 2024 - 10:00AM
Business Wire
- BrainTale unveils partnerships with leading research centers in
Europe and in the US to ultimately improve brain care through
biomarkers development.
- By powering precision neurology, the company provides the brain
research community with relevant quantitative imaging biomarkers to
improve patient care and clinical development of new
disease-modifying drugs.
BrainTale, a medtech deciphering white matter to enable
better brain care, spin-off of the Paris Region Greater
Hospitals, unveils today a selection of leading research centers
collaborations. For its partners, BrainTale offers innovative
regulatory-cleared software medical device combining relevant
standardized white matter quantification and AI solutions. Its
final goal is to assess brain damages evolutions with a high
efficiency and accuracy in neuroinflammatory and
neurodegenerative conditions to finally take appropriate
decisions, both in the day-to-day clinic and during drug
development.
Long underestimated in neuroscience, white matter, which
represents 60% to 80% of the human brain, plays a key role in its
proper functioning, development, and aging, whether normal or
pathological. Accordingly, since its creation in 2018, BrainTale
has been developing non-invasive, accessible, actionable and
clinically validated measurement and predictive tools for patients
suffering from brain diseases. With a strong collaborative
approach, the company’s ambition is to provide investigators with
relevant measure of the brain to improve patient care and
clinical development of new disease-modifying drugs.
BrainTale discloses a selection of its partners research
centers of excellence.
With Professor Fanny Mochel, MD, PhD in charge of the reference
center for Neurometabolic Diseases and Leukodystrophy at Hôpital
de la Pitié-Salpêtrière, Assistance Publique - Hôpitaux de
Paris (Paris, France), the collaboration focuses notably on
leukodystrophies. Professor Mochel comments: “Implementing
BrainTale’s biomarkers in our daily clinical practice and
integrating this white matter quantification method in the clinical
development brings significant value to our practice. Our expert
center aims at providing the right treatment at the right time, and
BrainTale's markers offer invaluable insights and benefits toward
achieving this”.
With Professors Ayham Alkhachroum, MD, MSc, Associate Professor
of Neurology and Neurocritical Care and Sebastian Koch, MD,
Professor of Clinical Neurology at the University of Miami
Miller School of Medicine (Miami, Florida, USA), the
collaboration will assess the benefits of BrainTale’s markers to
evaluate patient after acute cerebral hemorrhage. Professor
Alkhachroum comments: “There is an unmet clinical need to improve
patient’s management in acute cerebral hemorrhage by selecting
patients who can benefit from surgical evacuation. BrainTale’s
technology can provide key information to advance decisions toward
improving care in acute cerebral hemorrhage patients”.
Professor Rajiv Gupta is an Associate Professor at Harvard
Medical School, Medical Director at MGB Enterprise
Neuroradiology, Mass General Brigham, Vice Chair for Clinical
Operations in the Department. of Radiology at the Massachusetts
General Hospital (Boston, Massachusetts, USA). He is a member of
BrainTale’s Scientific Advisory Board with focus on traumatic
injuries and ageing diseases. ”Working with BrainTale empowers our
research with standardized and calibrated DTI metrics. It paves the
way for widespread diffusion of such biomarker both in research and
in clinical practice”, comments Professor Gupta.
An innovative, highly powerful tool and decisive enabler for
caregivers and drug developers.
BrainTale aims at contributing to a better understanding of
underlying mechanisms of several diseases and conditions, such as
cognitive disorders including Alzheimer’s disease, demyelinating
diseases such as leukodystrophies and multiple sclerosis, and acute
conditions such as traumatic brain injuries or stroke.
The non-invasive white matter quantification provided by
BrainTale is an innovative, highly powerful tool and decisive
enabler for caregivers and drug developers, offering objective
assessment to refine patient populations and monitor individual or
patient population responsiveness to new therapies in development.
By facilitating early detection, target identification, patient
stratification, and treatment monitoring, biomarkers enhance the
efficiency, effectiveness, and safety of drug development efforts
in the central nervous system complex and challenging therapeutic
environment. BrainTale’s biomarkers relevance in contemplated
conditions has been heavily supported by fast growing scientific
literature in the recent years. In practice, BrainTale’s software
solution offers quality controlled, reliable, standardized and
clinically validated reporting of diffusion MRI data processing
that dramatically reduce multicenter variability from any MRI
scanner type in standard clinical setting.
« Our collaborative approach is the foundation of BrainTale’
strategy to establish white matter measure as a reference to
ultimately contribute to a better brain care. We are thrilled to
unveil those first partnerships and intend to expand our network of
partners in the coming months”, comments Vincent Perlbarg,
BrainTale’s chief scientific officer and cofounder.
About BrainTale
BrainTale is an innovative European medtech company measuring
the brain through white matter quantification and standardization
based on a commercially available software medical device solution.
This regulatory-cleared AI software offers quality controlled,
non-invasive, reliable and clinically validated reports after
diffusion tensor MRI data processing. BrainTale enables drug
developers, leading academic researchers and physicians to improve
patient care by understanding neuroinflammatory and
neurodegenerative conditions, assess brain lesions evolutions and
take appropriate decisions in the clinic and during drug
development. BrainTale empowers the scientific and medical
community with objective measure to transform brain care.
Because brain diseases have become the medical issue of our
time, we can no longer wait. At BrainTale, we strongly believe that
by exploring better, we can treat faster, together.
For more information, please visit www.braintale.eu
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240506904199/en/
BrainTale – Lisa Marcheval, communication manager,
lisa.marcheval@braintale.eu
Press relations: Anna Casal +33650615571
casal.anna@gmail.com